Navigation Links
Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin
Date:3/16/2012

PHILADELPHIA, March 16, 2012 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.  James Tananbaum, MD, Foresite's founder and CEO, is joining Tarsa's Board of Directors.  Tarsa's existing venture capital investors—Novo A/S, MVM Life Science Partners and Quaker Partners—all participated in the new financing round. 

Following positive Phase III results and a successful pre-NDA meeting with the FDA, Tarsa is preparing to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) later this year for OSTORA™, its oral calcitonin tablet for the treatment of postmenopausal osteoporosis.  As the first once-daily oral calcitonin tablet expected to reach the market, OSTORA has the potential to offer patients and physicians the proven safety and efficacy of calcitonin with the advantage of significantly easier administration.  Proceeds from the Series B financing will support the NDA filing, preparation of a European Marketing Authorization Application (MAA) and essential pre-commercialization activities.

David Brand, President and CEO of Tarsa, said, "We are delighted to welcome experienced biotech entrepreneur and investor Jim Tananbaum as a Tarsa investor and board member, and we appreciate the continuing confidence of our existing investors who have supported Tarsa from the beginning.  This is an exciting time for the company as we prepare to file an NDA for OSTORA, and we are encouraged by the continuing strong interest in OSTORA from potential marketing partners."

"Tarsa is an excellent fit with Foresite's focus on late-stage healthcare companies developing significant medical advances," said Dr. Tananbaum.  "We believe there is substantial unmet need for additional safe and effective options for the treatment and prevention of osteoporosis, and we welcome the opportunity
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin
2. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
5. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
6. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
7. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
8. Orexigen Therapeutics to Present at Upcoming Conferences
9. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
10. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
11. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... University and Princeton University have created a new ... thermal and mechanical properties, could be used in ... polymer, a nanocomposite that incorporates functionalized, exfoliated graphene ... use that property to eventually create thermally stable, ...
... product to poultry, red meat and pork processing ... ... 19 Tasker Products Corp.,(OTC Bulletin Board: TKER), a distributor and ... has received authorization from the Food Safety and Inspection,Service ("FSIS") of ...
... SAN MARINO, Calif., May 19 Epeius Biotechnologies,announced today ... Rexin-G for,metastatic pancreatic cancer (Chawla et al., ASCO meeting, ... began in,2005 using lower doses of Rexin-G in a ... I/II study employed higher,dose-escalations of Rexin-G given i.v. two ...
Cached Biology Technology:By adding graphene, researchers create superior polymer 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 2Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries 3ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... , Marine Protected Areas (MPAs) are providing sea turtles with an ... the threats of fishing. A study by an international team of ... March), shows that 35 per cent of the world,s green turtles ... expected as only a small proportion of shallow oceans are designated ...
... York, NYMarch 18, 2012As nanotechnology becomes ever more ubiquitous, researchers ... and cheaper, in order to better diagnose diseases, learn more ... measuring them becomes more difficultthere is always a tradeoff between ... it is. And when a signal is very weak, the ...
... ,see-sawing, atmosphere over 2.5 billion years ago preceded the ... life on Earth, a new study has shown. , ... published today in the journal Nature Geoscience , ... a hydrocarbon-free state into a hydrocarbon-rich state similar to ...
Cached Biology News:Marine Protected Areas are keeping turtles safe 2Columbia Engineering and Penn researchers increase speed of single-molecule measurements 2Columbia Engineering and Penn researchers increase speed of single-molecule measurements 3Hazy shades of life on early Earth 2
...
ChIP-GLAS kit for H10K-B microarray chips. Contains ChIP kit, GLAS kit, and hybridization kit. Additional reagents are required. Please see manual for details. Contains sufficient reagent for 20 reac...
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Biology Products: